אקסטביה

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

INTERFERON BETA 1B 0.3 MG

Available from:

NOVARTIS PHARMA SERVICES AG

ATC code:

L03AB08

Pharmaceutical form:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Administration route:

S.C

Manufactured by:

BAYER PHARMA AG, GERMANY

Therapeutic group:

INTERFERON BETA-1B

Therapeutic indications:

Extavia is indicated for the treatment of:• For use in relapsing-remitting and relapsing-progressive multiple sclerosis. It is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite MS, and who have experienced at least two exacerbations over the last two years.Extavia reduces the frequency of clinical exacerbations.In secondary progressive multiple sclerosis Extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. Compared with placebo, patients receiving Extavia showed a statistically significant delay in time to progression of multiple sclerosis. The treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). Patients receiving Extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. See also Section 5.1 “Pharm

Authorization date:

2011-07-01